Laboratorios Farmaceuticos Rovi, S.A. (0ILL.L)
EUR 62.2
(0.97%)
EUR 62.2
(0.97%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 238.01 Million EUR | -13.95% |
| 2022 | 276.6 Million EUR | 36.19% |
| 2021 | 204.71 Million EUR | 108.94% |
| 2020 | 93.27 Million EUR | 61.34% |
| 2019 | 60.24 Million EUR | 115.83% |
| 2018 | 27.91 Million EUR | -2.79% |
| 2017 | 30.58 Million EUR | -44.93% |
| 2016 | 35.75 Million EUR | 69.27% |
| 2015 | 32.65 Million EUR | -12.98% |
| 2014 | 35.39 Million EUR | 21.51% |
| 2013 | 35.39 Million EUR | 14.93% |
| 2012 | 28.33 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 40.59 Million EUR | 57.72% |
| 2024 Q1 | 25.73 Million EUR | -64.8% |
| 2023 Q1 | 66.28 Million EUR | -36.39% |
| 2023 Q2 | 30.61 Million EUR | -53.8% |
| 2023 Q3 | 74.15 Million EUR | 142.19% |
| 2023 Q4 | 72.74 Million EUR | -1.9% |
| 2023 FY | - EUR | -11.86% |
| 2022 Q4 | 104.19 Million EUR | 80.7% |
| 2022 Q3 | 57.66 Million EUR | 39.98% |
| 2022 FY | - EUR | 36.19% |
| 2022 Q2 | 41.19 Million EUR | -44.26% |
| 2022 Q1 | 73.89 Million EUR | 16.63% |
| 2021 Q2 | 35.93 Million EUR | -6.51% |
| 2021 Q4 | 63.35 Million EUR | -3.1% |
| 2021 Q3 | 65.38 Million EUR | 81.96% |
| 2021 Q1 | 38.43 Million EUR | 85.15% |
| 2021 FY | - EUR | 108.94% |
| 2020 Q1 | 19.67 Million EUR | 77.87% |
| 2020 Q4 | 20.75 Million EUR | -22.94% |
| 2020 Q3 | 26.94 Million EUR | 21.16% |
| 2020 FY | - EUR | 61.34% |
| 2020 Q2 | 22.23 Million EUR | 13.03% |
| 2019 FY | - EUR | 115.83% |
| 2019 Q4 | 11.05 Million EUR | -45.78% |
| 2019 Q3 | 20.39 Million EUR | 64.93% |
| 2019 Q2 | 12.36 Million EUR | 6.46% |
| 2019 Q1 | 11.61 Million EUR | 437.82% |
| 2018 Q4 | 2.16 Million EUR | -78.46% |
| 2018 Q3 | 10.02 Million EUR | 106.87% |
| 2018 Q2 | 4.84 Million EUR | -51.27% |
| 2018 Q1 | 9.94 Million EUR | 1417.62% |
| 2018 FY | - EUR | -2.79% |
| 2017 Q3 | 3.87 Million EUR | -68.61% |
| 2017 Q1 | 9.93 Million EUR | 243.08% |
| 2017 FY | - EUR | -44.93% |
| 2017 Q4 | -755 Thousand EUR | -119.46% |
| 2017 Q2 | 12.35 Million EUR | 24.33% |
| 2016 Q2 | 10.56 Million EUR | -18.1% |
| 2016 FY | - EUR | 69.27% |
| 2016 Q4 | 2.89 Million EUR | -53.82% |
| 2016 Q3 | 6.27 Million EUR | -40.6% |
| 2016 Q1 | 12.89 Million EUR | 76.82% |
| 2015 FY | - EUR | -12.98% |
| 2015 Q4 | 7.29 Million EUR | 20.87% |
| 2015 Q3 | 6.03 Million EUR | -34.38% |
| 2015 Q2 | 9.19 Million EUR | -0.73% |
| 2015 Q1 | 9.26 Million EUR | 6.87% |
| 2014 Q4 | 8.66 Million EUR | 11.43% |
| 2014 FY | - EUR | 21.51% |
| 2014 Q1 | 8.02 Million EUR | 67.75% |
| 2014 Q2 | 10.92 Million EUR | 36.04% |
| 2014 Q3 | 7.77 Million EUR | -28.8% |
| 2013 Q2 | 10.23 Million EUR | 40.99% |
| 2013 Q4 | 4.78 Million EUR | -30.1% |
| 2013 FY | - EUR | 14.93% |
| 2013 Q3 | 6.84 Million EUR | -33.11% |
| 2013 Q1 | 7.26 Million EUR | 46.86% |
| 2012 Q4 | 4.94 Million EUR | 0.0% |
| 2012 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Boiron SA | 80.67 Million EUR | -195.017% |
| Vetoquinol SA | 104.58 Million EUR | -127.591% |
| Valneva SE | -64.51 Million EUR | 468.921% |
| AB Science S.A. | -9.28 Million EUR | 2664.562% |
| Nanobiotix S.A. | -34.01 Million EUR | 799.659% |
| PHAXIAM Therapeutics S.A. | -22.93 Million EUR | 1138.016% |
| Vivoryon Therapeutics N.V. | -28.35 Million EUR | 939.477% |
| BioSenic S.A. | -6.79 Million EUR | 3602.31% |
| ABIVAX Société Anonyme | -133.2 Million EUR | 278.682% |
| Formycon AG | 81.05 Million EUR | -193.656% |